Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer

Alexandre Bozec (1) , Nathalie Ebran (2) , Nina Radosevic-Robin (3) , Emmanuel Chamorey (4) , Hedi Ben Yahia , Serge Marcie (5) , Mathieu Gautier (6) , Frédérique Penault-Llorca (7, 8) , Gérard Milano (9)

1 Institut Universitaire de la Face et du Cou [Nice]
2 Laboratory of Solid Tumors Genetics
3 ERTICa - Equipe de recherche sur les traitements individualisés des cancers
4 Dept. of Statistics
5 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
6 LSI - Laboratoire de Simulation Interactive
7 UNICANCER/CJP - Centre Jean Perrin [Clermont-Ferrand]
8 IMoST - Imagerie Moléculaire et Stratégies Théranostiques
9 Unité de ciblage pharmacologique dans les cancers ORL

The purpose of this study was to investigate the effects of combining the phosphotidylinositol-3-kinase (PI3K) inhibitor buparlisib (BKM)120 with the anti-epidermal growth factor receptor (EGFR) agent cetuximab and radiotherapy (RT) on an orthotopic model of head and neck squamous cell carcinoma (HNSCC).

Mots clés: phosphatidylinositol 3-kinase (PIK3CA); head and neck cancer; epidermal growth factor receptor (EGFR); radiotherapy; targeted therapy

Domaines: Sciences du Vivant [q-bio]; Cancer

Alexandre Bozec, Nathalie Ebran, Nina Radosevic-Robin, Emmanuel Chamorey, Hedi Ben Yahia, et al.. Combination of phosphotidylinositol-3-kinase targeting with cetuximab and irradiation: A preclinical study on an orthotopic xenograft model of head and neck cancer. Archives of Otorhinolaryngology - Head & Neck Surgery, 2017, 39 (1), pp.151 - 159. ⟨10.1002/hed.24560⟩. ⟨hal-01675150⟩